Meeting
2024 ASCO Annual Meeting
Zotiraciclib for newly diagnosed or recurrent glioblastoma: Updated outcome and biomarker analysis.
Authors
Michael Weller
Department of Neurology, University Hospital Zurich, and Brain Tumor Centre, University Hospital and University of Zurich, University Hospital Zurich, Zurich, Switzerland
Michael Weller , Thierry Gorlia , Joerg Felsberg , Joost Jongen , Claude-Alain Maurage , Francois Ducray , Dorothee Gramatzki , Peter Hau , Olivier L. Chinot , Matthias Preusser , Stephanie Cartalat , Patrick Roth , Martin J. Van Den Bent , Julia Furtner , Maike Collienne , Guido Reifenberger , Tobias Weiss , Emilie Le Rhun
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 2058)
DOI
10.1200/JCO.2024.42.16_suppl.2058
Abstract #
2058
Poster Bd #
357
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Zotiraciclib (TG02) for newly diagnosed glioblastoma in the elderly or for recurrent glioblastoma: The EORTC 1608 STEAM trial.
First Author: Emilie Le Rhun
Poster
2023 ASCO Annual Meeting
Phase I and pharmacodynamic study of arsenic trioxide plus radiotherapy for newly diagnosed glioblastoma.
First Author: Samuel Ryu
Poster
2022 ASCO Annual Meeting
Phase I study of drug-resistant immunotherapy (DRI) with gene-modified autologous γδ T cells in patients with newly diagnosed glioblastoma multiforme (GBM) receiving maintenance temozolomide (TMZ).
First Author: Louis B. Nabors
Poster
2021 ASCO Annual Meeting
Scalp-sparing radiation with concurrent temozolomide and tumor treating fields (SPARE) for patients with newly diagnosed glioblastoma.
First Author: Ryan C Miller